Request Deal Involvement
Gilead Sciences completed the acquisition of MYR from High-Tech Gruenderfonds Management and Maxwell Biotech Venture Fund for c. $1.8bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
UBS
legal advisors
Freshfields Bruckhaus Deringer
legal advisors
Gibson Dunn & Crutcher
financial advisors
Goldman Sachs
legal advisors
Mayer Brown
legal advisors
Flick Gocke Schaumburg
or
Principals
target
MYR GMBH
bidder
GILEAD SCIENCES
vendor
HIGH-TECH GRUENDERFONDS MANAGEMENT GMBH (HTGF)
vendor
MAXWELL BIOTECH VENTURE
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite